CAR-T cell therapy: current limitations and potential strategies
Autor: | Rosalie M. Sterner, Robert C. Sterner |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_treatment
T-Lymphocytes Cancer immunotherapy Review Article Immunotherapy Adoptive lcsh:RC254-282 Cell therapy Antigen Neoplasms medicine Tumor Microenvironment Animals Humans Tumor microenvironment Receptors Chimeric Antigen business.industry Hematology Immunotherapy medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Chimeric antigen receptor Lymphoma Oncology B-cell leukemia Hematologic Neoplasms Cancer research business human activities |
Zdroj: | Blood Cancer Journal, Vol 11, Iss 4, Pp 1-11 (2021) Blood Cancer Journal |
ISSN: | 2044-5385 |
Popis: | Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors. |
Databáze: | OpenAIRE |
Externí odkaz: |